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Abstract 
Background: Considerable debate has arisen regarding the appropriateness of the test and treat malaria policy 
broadly recommended by the World Health Organization. While presumptive treatment has important drawbacks, the 
effectiveness of the test and treat policy can vary considerably across regions, depending on several factors such as 
baseline malaria prevalence and rapid diagnostic test (RDT) performance.
Methods: To compare presumptive treatment with test and treat, generalized linear mixed effects models were fit-
ted to data from 6510 children under five years of age from Burkina Faso’s 2010 Demographic and Health Survey.
Results: The statistical model results revealed substantial regional variation in baseline malaria prevalence (i.e., pre-
test prevalence) and RDT performance. As a result, a child with a positive RDT result in one region can have the same 
malaria infection probability as a demographically similar child with a negative RDT result in another region. These 
findings indicate that a test and treat policy might be reasonable in some settings, but may be undermined in others 
due to the high proportion of false negatives.
Conclusions: High spatial variability can substantially reduce the effectiveness of a national level test and treat 
malaria policy. In these cases, region-specific guidelines for malaria diagnosis and treatment may need to be for-
mulated. Based on the statistical model results, proof-of-concept, web-based tools were created that can aid in the 
development of these region-specific guidelines and may improve current malaria-related policy in Burkina Faso.
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Background
Presumptive treatment for malaria has historically been 
the norm throughout much of sub-Saharan Africa (SSA). 
However, multiple problems plague presumptive treat-
ment of malaria. First, considerable overlap in symptoms 
exists between malaria and other diseases [e.g., pneu-
monia; 1]. As a result, people that require treatment for 
other diseases might be inadvertently treated for malaria 
and sent home, with important consequences in terms 
of morbidity (and potentially mortality) and cost to the 
individual [2–4]. Second, there is substantial concern 
that presumptive treatment can promote more rapid 
emergence of anti-malarial drug resistance [5, 6]. Finally, 
as SSA countries transition to using artemisinin-based 
combination therapy (ACT) as their primary drugs for 
malaria treatment, presumptive treatment might be 
financially unsustainable given the higher costs of ACT 
[4, 7].
As a result of these concerns, the World Health Organi-
zation (WHO) has strongly promoted test and treat [8] as 
the primary malaria treatment policy for SSA countries. 
In this policy, “every suspected malaria case should be 
tested” and “every confirmed case should be treated with 
a quality-assured anti-malarial medicine” [8]. Because 
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microscopy (the gold standard method in the majority 
of SSA countries [9]) is often unavailable in remote rural 
settings, the implementation of test and treat has relied 
heavily on rapid diagnostic tests (RDTs) for parasitologi-
cal diagnostics [4, 5]. Recent studies have shown that the 
use of RDTs can lead to substantially improved targeting 
of anti-malarials when compared to only clinical diag-
nosis [10, 11]. In addition, despite the increased costs 
associated with using RDTs, test and treat might still be a 
cost-effective approach if it reduces the waste associated 
with providing ACT to uninfected individuals and if it 
decreases patient costs associated with repeated visits to 
health facilities ([2] but see [12]).
Despite the benefits associated with using RDTs, it has 
been repeatedly documented that providers and patients 
often ignore negative RDT results because of the poten-
tially high stakes associated with a false negative result [13–
15]. Indeed, while presumptive treatment certainly leads to 
over-treatment, test and treat can lead to both under and 
over-treatment because of false negative and false-posi-
tives RDT results, respectively. A recent Cochrane review 
indicates that RDTs have good overall performance (i.e., 
sensitivity greater than 90  % and specificity greater than 
95 % on average) but finds considerable variation between 
studies [16]. In particular, RDT performance varied sub-
stantially due to differences in the study population (e.g., 
treatment-seeking individuals versus a random sample of 
the population), the reference standard [e.g., microscopy or 
polymerase chain reaction (PCR)], type of RDT and RDT 
manufacturer, and environmental conditions (e.g., extreme 
temperature or humidity may damage RDT lots) [4, 9, 17]. 
As an example of potential limitations of RDTs, the widely 
used HRP2-based RDTs (e.g., Paracheck®) are Plasmodium 
falciparum specific and thus fail to detect other Plasmo-
dium species, will fail to detect P. falciparum if parasites 
have a mutation or deletion of the HRP-2 gene, and may 
detect the HRP-2 protein long after parasitaemia has been 
cleared from the host [18].
The relative merits of test and treat compared to pre-
sumptive treatment will depend on multiple factors, 
including performance characteristics of the diagnos-
tic tests (sensitivity and specificity), baseline infection 
prevalence, and costs (both direct and indirect) associ-
ated with false-positives and false-negatives. In this arti-
cle, Demographic and Health Survey (DHS) data from 
Burkina Faso were used to show that there is substantial 
spatial heterogeneity, even within regions of the same 
country, in relation to baseline infection prevalence and 
diagnostic test performance. As a result, a countrywide 
test and treat policy may yield unacceptably high lev-
els of false-negative results in some regions, suggesting 
that presumptive treatment might be a better alterna-
tive in these settings. Proof-of-concept, web-based tools 
were developed that can aid policy makers in developing 
region-specific malaria diagnostic and treatment policies.
Methods
Data
This analysis was based on DHS data collected in Bur-
kina Faso in 2010 (available at [19]). These data were col-
lected through a two-stage sampling design where the 
first stage consisted of sampling clusters (total of 574 
zones de dénombrement), with probability proportional 
to population size, and the second stage involved sam-
pling households within each cluster with equal prob-
ability based on a complete listing of all the households. 
Children between 6 and 59  months old were tested for 
malaria using microscopy and a P. falciparum HRP2 
protein-based RDT (Paracheck®) after obtaining consent 
from the caregiver. RDT results were available 15  min 
after blood collection while microscopy slides were 
later evaluated at the Centre National de Recherche et 
de Formation sur le Paludisme (CNRFP), the reference 
laboratory for malaria in Burkina Faso. Two independ-
ent technicians read each blood slide and, in the case of 
discrepancy, a third microscopist evaluated the slide [20, 
21]. In total, microscopy and RDT results were collected 
from 6510 children. Additional details regarding data col-
lection and diagnostic tests can be found in [20, 21].
Statistical models
Two malaria biomarkers [microscopy (M) and RDT (R)] 
were modelled as a function of individual level covari-
ates (X) using probit mixed regression models, where 
the intercept and slope parameters were allowed to 
vary for each region. Only relatively simple covariates 
were included in the statistical models, such as fever in 
the previous two weeks (no =  0, yes =  1), age (catego-
rized into five age groups: 6–11, 12–23, 24–35, 36–47, 
48–60  months), gender (0  =  girl, 1  =  boy), and urban 
(no = 0, yes = 1). These covariates were chosen because 
they have been shown elsewhere to be important malaria 
predictors and because they can be readily assessed with 
minimal training [22, 23].
The model for each biomarker had the same over-
all specification. Let a binary response variable (either 
microscopy or RDT result) for the i-th individual in the 
j-th region be denoted by yij. Assume that:
where  is the standard normal cumulative distribution 
function, xij1, . . . , xijP are covariates, and β0j , . . . ,βPj are 
regression parameters. Standard priors and hyper-priors 
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where  is a diagonal matrix with diagonal elements 
[100, 1, 1, . . . , 1].
Notice that αp summarizes the effect of covariate p 
across all regions while τ 2p  measures the variability of the 
region-specific effects βpj. Although these models are 
fairly standard and can be fitted in a frequentist or Bayes-
ian framework [24], a Bayesian framework was chosen 
to better represent parameter uncertainty in outputs. 
Regression slope estimates for which the 95  % credible 
interval did not include zero were judged to be statisti-
cally significant.
These individual models were combined using Bayes 
theorem. Let (M|X) denote the model for micros-
copy results (M) given covariates (X). Furthermore, let 
(R|M,X) denote the model for the RDT results (R) given 
microscopy results (M) and covariates (X). Then, the 
probability of malaria infection (assuming microscopy is 
the gold standard) given RDT results (R) and covariate 
values (X) is given by:
The approach described above was chosen because 
of the interpretability of the results (e.g., the RDT mod-
els reveal how RDT sensitivity and specificity are influ-
enced by covariates) and because it enables interactions 
to emerge naturally (e.g., the effect of age on RDT per-
formance may vary as a function of infection status). 
Additional details regarding these statistical models are 
provided in Additional file 1. All models were fitted, and 
figures were created, using customized R code [25].
One potential concern with the model described above 
is that sample size might not be large enough within 
each strata to allow for reliable estimation of the differ-
ent regression parameters. This was not a significant hin-
drance to this analysis given that all strata had at least 30 
individuals. Finally, a ten-fold, cross-validation exercise 
revealed that the model described above had better out-
of-sample predictive performance than two other more 
standard statistical models (Additional file 2).
Online tools
In order to broaden the application of this analysis, two 
online tools were developed that enable policy makers 
and other potential users to interact with our statistical 
modeling results. These tools were created using ‘Shiny’ 
[26], a freely available package in R that enables the crea-
tion of interactive web applications without requiring 
τp ∼ Unif (0, 100)
α ∼ N (0,�)
p(M = 1|R,X)
=
p(R|M = 1,X)p(M = 1|X)
p(R|M = 0,X)p(M = 0|X)+ p(R|M = 1,X)p(M = 1|X)
modellers to know HTML, CSS, or JavaScript. These 
proof-of-concept tools were created to help bridge the 
gap between our statistical models and actionable policy 
decisions.
Results
Overall, individuals in urban areas tended to have a much 
lower risk of malaria and this risk tended to increase 
significantly with age (Fig.  1a). Furthermore, there was 
considerable heterogeneity between regions regarding 
malaria risk differences in rural and urban areas (Fig. 1b). 
In relation to RDT performance, the models indicate 
that the probability of a true positive RDT result (RDT 
sensitivity) was not consistently influenced by any of the 
covariates (Fig.  1c). On the other hand, the probability 
of a false positive RDT result was significantly higher for 
older children (two to four years old children) and was 
lower for individuals in urban areas (Fig. 1e). Both RDT 
sensitivity and specificity varied considerably from region 
to region (‘intercept’ in Fig. 1d, f ).
What do the findings described above imply in rela-
tion to the post-test probability of infection p(M|R,X)? 
RDT results substantially changed the probability of 
infection (red and blue circles in Fig. 2) compared to the 
pre-test probability of infection (i.e., baseline prevalence; 
black circles in Fig. 2), which indicate that RDTs are very 
informative regarding the likelihood of infection. How-
ever, individuals with a negative RDT result still have a 
20–70 % chance of being infected in rural settings (blue 
solid circles in Fig.  2a–c). For instance, the infection 
probability of a four years old child with an RDT-negative 
result in rural areas of the Hauts Basins region (blue solid 
circles in Fig. 2c) can be equal to the infection probabil-
ity of a RDT-positive child of the same age in the same 
region from an urban area (red solid circles in Fig.  2f ). 
Three regions in Fig. 2 were selected to illustrate the pat-
terns between infection status and the main covariates 
but an online tool was also developed to enable users to 
explore all factors included in our analysis for all regions 
(available through the website [27]).
In addition to variation between urban and rural areas 
within a particular region, this analysis also identified 
substantial differences between regions. For instance, 
RDT results seem more informative in the Sud-Ouest 
region than in the Sahel region (compare vertical distance 
between the blue and red solid circles in Fig. 2a, b, d, e). 
Similarly, although urban areas tend to have lower infec-
tion probability than rural areas, there seems to be sub-
stantial heterogeneity among urban areas. For example, 
probability of infection in urban areas of the Hauts Basins 
region is much lower than that in urban areas in Sud-
Ouest and Sahel (compare Fig. 2d–f). These results sug-
gest a complicated relationship between RDT outcomes 
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and post-test probability of infection, indicating that a 
single malaria diagnosis and treatment policy even just 
for urban areas in Burkina Faso may not be effective. For 
instance, a test and treat policy might not be suitable for 
urban areas in the Sahel region, given the high probabil-
ity of infection (>0.3) of RDT-negative children, whereas 
it might be a suitable option for urban areas in the Hauts 
Basin region.
The relevance of spatial heterogeneity for malaria 
diagnosis and treatment policy can be illustrated with 
a hypothetical example. For instance, if policy makers 
decided that it is unacceptable to use a diagnostic test 
with a probability of false-negative results above 30 % (for 
example), then presumptive treatment would be recom-
mended for all rural areas in Burkina Faso and for urban 
settings in the Sahel and Est regions. In another online 
tool that we have developed (available through the web-
site [28]), readers can explore the geographic implications 
regarding recommended presumptive treatment for differ-
ent thresholds of the probability of false-negative results.
(See figure on previous page.) 
Fig. 1 Parameter estimates (circles) and 95 % credible intervals (vertical lines). Results for the 3 different statistical models are displayed in each row 
of panels: microscopy (M|X; a, b), RDT sensitivity (R|M = 1,X; c, d), and one minus RDT specificity (R|M = 0,X; e, f). Age groups 1, 2, 3, and 4 refer to 
children 12–23, 24–35, 36–47, and 48–59 months old, respectively. Left panels depict the average of the random slope parameter p in model k (α(k)p ). 
Statistically significant parameters (i.e., 95 % credible intervals do not overlap with zero) are highlighted with black lines while non-significant results 
are depicted with grey lines. Right panels depict regional heterogeneity in effect sizes, represented by the variance of random parameter p in model 
k (τ 2(k)p ). A detailed description of our statistical model is provided in Additional file 1. Se and Sp stand for sensitivity and specificity, respectively
Fig. 2 Probability of malaria infection for three regions in Burkina Faso (Sud-Ouest, Sahel, and Hauts Basins). Results are shown as a function of 
age group, urban/rural setting, and RDT result, for boys with no fever history in the previous 2 weeks. Age groups 0, 1, 2, 3, and 4 refer to children 
6–11, 12–23, 24–35, 36–47, 48–59 months old, respectively. Pre-test probability of infection is shown in black, post-test probability of infection for 
RDT-negative individuals (RDT −) is shown in blue, and post-test probability of infection for RDT-positive individuals (RDT +) is shown in red. A large 
vertical distance between the red and blue solid circles indicates that RDT results are very informative regarding infection status
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Discussion
The statistical model for malaria microscopy confirms 
several of the relationships often described in malaria 
epidemiology in endemic regions, such as the increase 
in malaria prevalence with age [29] and generally higher 
prevalence in rural settings when compared to urban 
areas [30]. However, the impact of some of these fac-
tors (e.g., age and urban vs rural settings) on RDT per-
formance is less commonly explored [but see 23, 31, 32]. 
The modelling results suggest that RDT specificity is 
higher for children in urban settings and younger chil-
dren (Fig. 1e). This might be due to these children being 
less likely to have had a past malaria infection since false 
positives will typically arise on individuals with past 
malaria infections due to the relatively long time that 
the target antigen persists in the blood [33, 34]. Alterna-
tively, these RDT results might be correct but microscopy 
might have failed to detect these infected individuals, 
which is likely to be a common phenomenon for indi-
viduals with low parasitaemia levels [35–37]. Finally, sub-
stantial geographical variation was observed regarding 
RDT sensitivity and specificity. Multiple reasons could 
explain this, including differences in the proportion of 
individuals with past exposure to malaria, exposure of 
RDTs to excessive heat and humidity during storage and 
distribution, intra-species diversity of the target antigen, 
and the parasite stage-specific expression of the antigen 
[4, 17, 38].
Most importantly, these multiple statistical models 
were combined to highlight the substantial spatial heter-
ogeneity in malaria risk given RDT results. Under a coun-
trywide test and treat policy, in some regions children 
with very similar infection probabilities might be denied 
treatment in a rural setting (due to a negative RDT result) 
but receive treatment in an urban setting (due to a posi-
tive RDT result). To avoid this, region-specific guide-
lines for malaria diagnosis and treatment might need to 
be developed, a process that can be potentially aided by 
the developed tool. Differently from past approaches that 
have relied on a threshold for the pre-test probability of 
clinical malaria [39], the proposed tool focuses on the 
probability of false-negative results to determine which 
areas a test and treat policy might be warranted. Obvi-
ously there are a number of other considerations that 
should be taken into account when determining policies 
for malaria diagnosis and treatment. For instance, the 
results of this study, in conjunction with direct and indi-
rect cost information, would be very informative for pol-
icy makers if used in a decision-theoretic framework. In 
particular, local heterogeneities (e.g., longer travel times 
and lower wages in rural settings) may play an impor-
tant role in determining what is most cost effective in 
each setting. Nevertheless, this analysis clearly illustrates 
important shortcomings of a uniform test and treat pol-
icy across Burkina Faso.
An important caveat to this study is that the data con-
tain children that were sampled regardless of their symp-
toms and there was no information on symptoms on the 
day of the survey. Although presence of fever during the 
previous two weeks was controlled for (a variable that 
was surprisingly unimportant), baseline malaria preva-
lence and RDT performance are likely to be different 
for individuals that seek help in health facilities due to 
the presence of symptoms. Thus, using data on syndro-
mic individuals would certainly be more appropriate 
when designing policies for malaria diagnosis and treat-
ment at health facilities. Unfortunately, data over large 
geographical regions on treatment-seeking individuals 
that are tested with multiple diagnostic methods (i.e., 
microscopy and RDT) are scarce. Additional studies are 
warranted to determine if similar spatial heterogeneities 
are found when using syndromic data in Burkina Faso 
and in other malaria-endemic regions. Nevertheless, the 
results in this article are relevant for determining where 
a mass screen and treat strategy is likely to be more effec-
tive than a mass drug administration approach, a topic 
that has received renewed interest by policy makers 
and researchers and for which evidence is still relatively 
scarce in moderate to high malaria transmission areas 
([40] but see [31, 41]). Finally, although this study focuses 
on children under five years, similar ideas are likely to 
be applicable for comparing intermittent screening and 
treatment (IST) as an alternative approach to diagnosis 
by symptoms only or intermittent preventive treatment 
for pregnant women [42–45].
One potential concern regarding this study refers to 
using microscopy as the gold standard method. Although 
routine microscopy can yield highly variable results, it 
is important to note that microscopy was conducted by 
the parasitology laboratory of the CNRFP, the reference 
laboratory for malaria in Burkina Faso. Staff at this centre 
participate in various quality control programmes in par-
asitology (e.g., proficiency testing programmes to comply 
with the College of American Pathologists and WHO-
AFRO checklists) and are subject to rigorous internal and 
external quality control [21, 46]. Furthermore, DHS sur-
veys across the majority of the SSA countries have relied 
on expert microscopy and these microscopy results have 
been extensively used by the scientific community as the 
gold standard (e.g., to create national malaria prevalence 
maps). Finally, expert microscopy is commonly used as 
the gold standard method against which RDT is evalu-
ated [20, 34, 47, 48]. Although even expert microscopy 
can miss a large proportion of asymptomatic carriers 
[41], often because of low total parasite density [35–37], 
this does not explain the high proportion of positive 
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microscopy but negative RDT results (i.e., false-negative 
results) found here in some regions.
Why is there such a high proportion of false-negative 
results? There may be multiple non-exclusive reasons. 
RDTs might have been exposed to extreme conditions of 
temperature and humidity which may have compromised 
its performance (as documented for Burkina Faso in [49]). 
The prevalence of other Plasmodium species might have 
been high (e.g., a 13.2 % prevalence of Plasmodium malar-
iae was found in a village in rural Burkina Faso in 2010 
[50]), undermining a RDT that exclusively targets P. fal-
ciparum. Finally, it has been shown that the performance 
of RDT (both pLDH-based and HRP-2-based) is reduced 
in patients with lower parasite density [31, 51, 52]. While 
patients with false negative results may be deemed clini-
cally irrelevant given their likely low parasite density [51, 
53], this reasoning does not apply here because this study 
focuses on children under five and even low parasite den-
sities are likely to result in fever [51] and lower mean hae-
moglobin levels [54] for this age group. Furthermore, it 
has been shown that malaria transmission readily occurs 
at low parasitaemia [55, 56] and that low parasitaemia 
infections significantly contribute to malaria transmis-
sion due to the high prevalence of these infections [35, 
56, 57]. These findings suggest that, even if false negative 
results arise from low parasitaemia, it remains important 
to treat these individuals. It is also important to realize 
that, for children with very high malaria prevalence (e.g., 
older children in rural areas), even a RDT with high sen-
sitivity is likely to generate a relatively high probability of 
false negatives [58]. For instance, if sensitivity is 0.95 and 
malaria prevalence is 0.8, Bayes theorem indicates that the 
probability of false negative is
In other words, among all RDT negative children, at 
least one out of six will actually be infected with malaria. 
In this calculation, RDT specificity p(R = 0|M = 0) was 
assumed to be 100 % but the probability of false negative 
results can be even higher for lower values of RDT speci-
ficity. Indeed, the above scenario is very optimistic. For 
instance, using the same DHS data from Burkina Faso, 
Samadoulougou et al. [20] have shown that RDT sensitiv-
ity was actually closer to 90 % (89.9 %, with 95 % confi-
dence interval CI of 89–90.8) and specificity was very low 
(50.4 %, 95 % CI of 48.3–52.6).
Another important remark is that the 2010 DHS data 
for Burkina Faso was predominantly collected during 
p(M = 1|R = 0)
≥
p(R = 0|M = 1)p(M = 1)
p(R = 0|M = 1)p(M = 1)+ p(R = 0|M = 0)p(M = 0)
=
(1− 0.95)× 0.8




the rainy season. As a result, the well documented sea-
sonal differences in malaria risk and RDT performance 
in Burkina Faso [32, 41, 44, 51–53, 56, 59–65] were not 
accounted for in the statistical models. These seasonal 
differences can be as dramatic as the geographical dif-
ferences described here. For instance, similar to the 
observed pattern for the urban vs rural areas in the Hauts 
Basins region, a negative RDT test has been shown to 
reduce the probability of malaria to almost zero during 
the dry season but not in the rainy season [51]. An impor-
tant implication of not taking into account seasonality in 
our models is that any policy derived from these tools is 
likely to be applicable only for the rainy season. Finally, 
DHS data were collected during approximately the same 
time period for each region except for the Centre, Cen-
tre-Nord, Nord, and Plateau Central regions. Because 
of these differences regarding when data were collected 
in each region, geographical comparisons involving the 
regions cited above should be interpreted carefully as 
they may be confounded with seasonality effects.
Conclusion
Similar to the findings in [39, 51], the analysis presented 
here suggests that a generalized test-based policy should 
not be used uniformly across all contexts. In particular, 
even with improved diagnostic methods (e.g., positive 
control wells; [66]), the ‘back-of-the-envelope’ calcula-
tion above reveals how the probability of false-negative 
results will still be relatively large when prevalence is 
high. Unfortunately, because prevalence varies signifi-
cantly even within the same region (e.g., according to 
age groups, season, rural vs urban), developing sound 
and straightforward diagnostic guidelines remains an 
important challenge. This article has shown how dif-
ferent statistical models can come together to inform 
context specific guidelines for malaria diagnosis and 
treatment, potentially improving the use of resources 
(e.g., reducing wasted RDTs in regions where false-neg-
ative probabilities are very high) and reducing malaria 
burden. Ultimately, bridging the gap between informa-
tion users and these statistical models will be critical 
to foster evidence-based decision making and better 
resource allocation.
Authors’ contributions
DV wrote the first draft, conducted the analyses, and developed the online 
tools. PA and JM provided critical feedback and substantially edited the manu-
script. All authors read and approved the final manuscript.
Additional files
Additional file 1. Description of statistical models.
Additional file 2. Model validation.
Page 8 of 9Valle et al. Malar J  (2016) 15:513 
Acknowledgements
We thank Joanna Tucker-Lima and Paul Psychas for providing feedback on an 
earlier version of this manuscript.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials




This research was funded through an Early Career Seed Fund to DV from the 
University of Florida.
Received: 25 August 2016   Accepted: 7 October 2016
References
 1. Källander K, Nsungwa-Sabiiti J, Peterson S. Symptom overlap for malaria 
and pneumonia—policy implications for home management strategies. 
Acta Trop. 2004;90:211–4.
 2. Hume JCC, Barnish G, Mangal T, Armazio L, Streat E, Bates I. Household 
cost of malaria overdiagnosis in rural Mozambique. Malar J. 2008;7:33.
 3. Amexo M, Tolhurst R, Barnish G, Bates I. Malaria misdiagnosis: effects on 
the poor and vulnerable. Lancet. 2004;364:1896–8.
 4. Bell D, Wongsrichanalai C, Barnwell JW. Ensuring quality and access for malaria 
diagnosis: how can it be achieved? Nature Rev Microbiol. 2006;4:682–95.
 5. D’Acremont V, Lengeler C, Mshinda H, Mtasiwa D, Tanner M, Genton B. Time 
to move from presumptive malaria treatment to laboratory-confirmed diag-
nosis and treatment in African children with fever. PLoS Med. 2009;6:e252.
 6. Bloland PB. Drug resistance in malaria. Geneva: World Health Organization, 
Department of Communicable Disease Surveillance and Response; 2001.
 7. Abeku TA, Kristan M, Jones C, Beard J, Mueller DH, Okia M, et al. Determi-
nants of the accuracy of rapid diagnostic tests in malaria case manage-
ment: evidence from low and moderate transmission settings in the East 
African highlands. Malar J. 2008;7:202.
 8. World Health Organization. T3: Test. Treat. Track initiative. http://www.
who.int/malaria/areas/test_treat_track/en/.
 9. Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH. 
A review of malaria diagnostic tools: microscopy and rapid diagnostic 
test (RDT). Am J Trop Med Hyg. 2007;77:119–27.
 10. Ansah EK, Epokor M, Whitty CJM, Yeung S, Hansen KS. Cost-effectiveness 
analysis of introducing RDTs for malaria diagnosis as compared to micros-
copy and presumptive diagnosis in central and peripheral public health 
facilities in Ghana. Am J Trop Med Hyg. 2013;89:724–36.
 11. Ansah EK, Narh-Bana S, Epokor M, Akanpigbiam S, Quartey AA, Gyapong 
J, et al. Rapid testing for malaria in settings where microscopy is available 
and peripheral clinics where only presumptive treatment is available: a 
randomised controlled trial in Ghana. BMJ. 2010;340:c930.
 12. Yukich J, D’Acremont V, Kahama J, Swai N, Lengeler C. Cost savings with 
rapid diagnostic tests for malaria in low-transmission areas: evidence 
from Dar es Salaam, Tanzania. Am J Trop Med Hyg. 2010;83:61–8.
 13. Cohen J, Dupas P, Schaner S. Price subsidies, diagnostic tests, and target-
ing of malaria treatment: evidence from a randomized controlled trial. 
Am Econ Rev. 2015;105:609–45.
 14. Bisoffi Z, Sirima BS, Angheben A, Lodesani C, Gobbi F, Tinto H, et al. Rapid 
malaria diagnostic tests vs. clinical management of malaria in rural Bur-
kina Faso: safety and effect on clinical decisions. A randomized trial. Trop 
Med Int Health. 2009;14:491–8.
 15. Hamer DH, Ndhlovu M, Zuovac D, Fox M, Yeboah-Antwi K, Chanda P, et al. 
Improved diagnostic testing and malaria treatment practices in Zambia. 
JAMA. 2007;297:2227–31.
 16. Abba K, Deeks JJ, Olliaro P, Naing CM, Jackson SM, Takwoingi Y, Donegan 
S, Garner P. Rapid diagnostic tests for diagnosing uncomplicated P. 
falciparum malaria in endemic countries. Cochrane Database Syst Rev. 
2011;(7):CD008122. doi:10.1002/14651858.CD008122.pub2.
 17. Cheng A, Bell D. Evidence behind the WHO guidelines: hospital care for 
children: what is the precision of rapid diagnostic tests for malaria? J Trop 
Pediatr. 2006;52:386–9.
 18. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 
2002;15:66–78.
 19. ICF. The Demographic and Health Surveys (DHS) Program. http://www.
dhsprogram.com/.
 20. Samadoulougou S, Kirakoya-Samadoulougou F, Sarrassat S, Tinto H, Bak-
iono F, Nebie I, et al. Paracheck rapid diagnostic test for detecting malaria 
infection in under five children: a population-based survey in Burkina 
Faso. Malar J. 2014;13:1.
 21. Institut National de la Statistique et de la Demographie, ICF International. 
Enquete Demographique et de Santé et à Indicateurs Multiples du 
Burkina Faso 2010. Calverton: INSD and ICF International; 2012.
 22. Adigun AB, Gajere EN, Oresanya O, Vounatsou P. Malaria risk in Nigeria: 
Bayesian geostatistical modelling of 2010 malaria indicator survey data. 
Malar J. 2015;14:156.
 23. Magalhaes RJS, Clements ACA. Mapping the risk of anaemia in preschool-
age children: the contribution of malnutrition, malaria, and helminth 
infections in West Africa. PLoS Med. 2011;8:e1000438.
 24. Gelman A, Hill J. Data analysis using regression and multilevel/hierarchi-
cal models. Cambridge: Cambridge University Press; 2007.
 25. R Core Team. A language and environment for statistical computing. 
Vienna: R Foundation for Statistical Computing; 2013.
 26. RStudio. Shiny: a web application framework for R. http://www.shiny.
rstudio.com/.
 27. Valle D, Millar J, Amratia P. Probability of malaria infection in Burkina Faso. 
https://denisvalle.shinyapps.io/burkina_faso_tool/.
 28. Valle D, Millar J, Amratia P. Regions for presumptive treatment in Burkina 
Faso. https://denisvalle.shinyapps.io/burkina_faso_map/.
 29. Smith DL, Guerra CA, Snow RW, Hay SI. Standardizing estimates of the 
Plasmodium falciparum parasite rate. Malar J. 2007;6:131.
 30. Pond BS. Malaria indicator surveys demonstrate a markedly lower preva-
lence of malaria in large cities of sub-Saharan Africa. Malar J. 2013;12:313.
 31. Tiono AB, Ouedraogo A, Diarra A, Coulibaly S, Soulama I, Konate AT, et al. 
Lessons learned from the use of HRP-2 based rapid diagnostic test in 
community-wide screening and treatment of asymptomatic carriers of 
Plasmodium falciparum in Burkina Faso. Malar J. 2014;13:30.
 32. Maltha J, Guiraud I, Lompo P, Kabore B, Gillet P, Van Geet C, et al. Accuracy 
of PfHRP2 versus Pf-pLDH antigen detection by malaria rapid diagnostic 
tests in hospitalized children in a seasonal hyperendemic malaria trans-
mission area in Burkina Faso. Malar J. 2014;13:20.
 33. Kyabayinze DJ, Tibenderana JK, Odong GW, Rwakimari JB, Counihan H. 
Operational accuracy and comparative persistent antigenicity of HRP2 
rapid diagnostic tests for Plasmodium falciparum malaria in a hyperen-
demic region of Uganda. Malar J. 2008;7:221.
 34. Swarthout TD, Counihan H, Senga RKK, van den Broek I. Paracheck-Pf 
accuracy and recently trated Plasmodium falciparum infections: is there a 
risk of over-diagnosis? Malar J. 2007;6:58.
 35. Slater HC, Ross A, Ouedraogo A, White LJ, Nguon C, Walker PGT, et al. 
Assessing the impact of next-generation rapid diagnostic tests on Plasmo-
dium falciparum malaria elimination strategies. Nature. 2015;528:S94–101.
 36. Kattenberg JH, Tahita CM, Versteeg IAJ, Tinto H, Traore Coulibaly M, 
D’Alessandro U, et al. Evaluation of antigen detection tests, microscopy, 
and polymerase chain reaction for diagnosis of malaria in peripheral 
blood in asymptomatic pregnant women in Nanoro, Burkina Faso. Am J 
Trop Med Hyg. 2012;87:251–6.
 37. Hopkins H, Bebell L, Kambale W, Dokomajilar C, Rosenthal PJ, Dorsey G. 
Rapid diagnostic tests for malaria at sites of varying transmission intensity 
in Uganda. J Infect Dis. 2008;197:510–8.
 38. Baker J, McCarthy J, Gatton M, Kyle DE, Belizario V, Luchavez J, et al. 
Genetic diversity of Plasmodium falciparum Histidine-Rich Protein 2 
(PfHRP2) and its effect on the performance of PfHRP2-Based rapid diag-
nostic tests. J Infect Dis. 2005;192:870–7.
 39. Bisoffi Z, Tinto H, Sirima BS, Gobbi F, Angheben A, Buonfrate D, et al. 
Should malaria treatment be guided by a point of care rapid test? A 
threshold approach to malaria management in rural Burkina Faso. PLoS 
ONE. 2013;8:e58019.
 40. WHO. Mass drug administration, mass screening and treatment and focal 
screening and treatment for malaria. Geneva: World Health Organization; 
2015.
Page 9 of 9Valle et al. Malar J  (2016) 15:513 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 41. Tiono AB, Guelbeogo MW, Sagnon NF, Nebie I, Sirima SB, Mukhopadhyay 
A, et al. Dynamics of malaria transmission and susceptibility to clinical 
malaria episodes following treatment of Plasmodium falciparum asymp-
tomatic carriers: results of a cluster-randomized study of community-
wide screening and treatment, and a parallel entomology study. BMC 
Infect Dis. 2013;13:535.
 42. Tagbor H, Cairns M, Bojang K, Coulibaly SO, Kayentao K, Williams J, et al. 
A non-inferiority, individually randomized trial of intermittent screening 
and treatment versus intermittent preventive treatment in the control of 
malaria in pregnancy. PLoS ONE. 2015;10:e0132247.
 43. Tahita MC, Tinto H, Menten J, Ouedraogo J-B, Guiguemde RT, van 
Geertruyden JP, et al. Clinical signs and symptoms cannot reliably predict 
Plasmodium falciparum malaria infection in pregnant women living in an 
area of high seasonal transmission. Malar J. 2013;12:464.
 44. Williams JE, Cairns M, Njie F, Quaye SL, Awine T, Oduro A, et al. The 
performance of a rapid diagnostic test in detecting malaria infection in 
pregnant women and the impact of missed infections. Clin Infect Dis. 
2015;62:837–44.
 45. Kyabayinze DJ, Zongo I, Cunningham J, Gatton M, Angutoko P, Ategeka 
J, et al. HRP2 and pLDH-based rapid diagnostic tests, expert microscopy, 
and PCR for detection of malaria infection during pregnancy and at deliv-
ery in areas of varied transmission: a prospective cohort study in Burkina 
Faso and Uganda. PLoS ONE. 2016;11:e0156954.
 46. Ibrahim F, Dosoo D, Kronmann KC, Ouedraogo I, Anyorigiya T, Abdul H, 
et al. Good clinical laboratory practices improved proficiency testing 
performance at clinical trials centers in Ghana and Burkina Faso. PLoS 
ONE. 2012;7:e39098.
 47. Nkrumah B, Acquah SEK, Ibrahim L, May J, Brattig N, Tannich E, et al. 
Comparative evaluation of two rapid field tests for malaria diagnosis: 
Partec Rapid Malaria Test and Binax Now Malaria Rapid Diagnostic Test. 
BMC Infect Dis. 2011;11:143.
 48. Ansah EK, Narh-Bana S, Affran-Bonful H, Bart-Plange C, Cundill B, 
Gyapong M, et al. The impact of providing rapid diagnostic malaria tests 
on fever management in the private retail sector in Ghana: a cluster 
randomized trial. BMJ. 2015;350:h1019.
 49. Albertini A, Lee E, Coulibaly SO, Sleshi M, Faye B, Mationg ML, et al. 
Malaria rapid diagnostic test transport and storage conditions in Burkina 
Faso, Senegal, Ethiopia and the Philippines. Malar J. 2012;11:406.
 50. Gneme A, Guelbeogo WM, Riehle MM, Tiono AB, Diarra A, Kabre GB, et al. 
Plasmodium species occurrence, temporal distribution and interaction in 
a child-aged population in rural Burkina Faso. Malar J. 2013;12:67.
 51. Bisoffi Z, Sirima SB, Menten J, Pattaro C, Angheben A, Gobbi F, et al. Accu-
racy of a rapid diagnostic test on the diagnosis of malaria infection and of 
malaria—attributable fever during low and high transmission season in 
Burkina Faso. Malar J. 2010;9:192.
 52. Diarra A, Nebie I, Tiono A, Sanon S, Soulama I, Ouedraogo A, et al. 
Seasonal performance of a malaria rapid diagnostic test at community 
health clinics in a malaria-hyperendemic region of Burkina Faso. Parasit 
Vectors. 2012;5:103.
 53. Bisoffi Z, Sirima SB, Meheus F, Lodesani C, Gobbi F, Angheben A, et al. 
Strict adherence to malaria rapid test results might lead to a neglect of 
other dangerous diseases: a cost benefit analysis from Burkina Faso. Malar 
J. 2011;10:226.
 54. McElroy PD, ter Kuile FO, Lal AA, Bloland PB, Hawley WA, Oloo AJ, et al. 
Effect of Plasmodium falciparum parasitemia density on hemoglobin 
concentrations among full-term, normal birth weight children in 
western Kenya, IV. The Asembo Bay cohort project. Am J Trop Med Hyg. 
2000;62:504–12.
 55. Churcher TS, Bousema Walker M, Drakeley C, Schneider P, Ouedraogo 
AL, et al. Predicting mosquito infection from Plasmodium falciparum 
gametocyte density and estimating the reservoir of infection. eLife. 
2013;2:e00626.
 56. Ouedraogo AL, Goncalves BP, Gneme A, Wenger EA, Guelbeogo MW, 
Ouedraogo A, et al. Dynamics of the human infectious reservoir for 
malaria determined by mosquito feeding assasys and ultrasensitive 
malaria diagnosis in Burkina Faso. J Infect Dis. 2016;213:90–9.
 57. Ouedraogo AL, Bousema T, Schneider P, de Vlas SJ, Ilboudo-Sanogo E, 
Cuzin-Ouattara N, et al. Substantial contribution of submicroscopical 
Plasmodium falciparum gametocyte carriage to the infectious reservoir in 
an area of seasonal transmission. PLoS ONE. 2009;4:e8410.
 58. Graz V, Willcox M, Szeless T, Rougemont A. “Test and treat” or presumptive 
treatment for malaria in high transmission situations? A reflection on the 
latest WHO guidelines. Malar J. 2011;10:136.
 59. Ouedraogo A, Tiono AB, Diarra A, Sanon S, Yaro JB, Ouedraogo E, et al. 
Malaria morbidity in high and seasonal malaria transmission area of 
Burkina Faso. PLoS ONE. 2013;8:e50036.
 60. im Kampe EO, Muller O, Sie A, Becher H. Seasonal and temporal trends in 
all-cause and malaria mortality in rural Burkina Faso, 1998–2007. Malar J. 
2015;14:300.
 61. Beiersmann C, Bountogo M, Tiendrebeogo J, de Allegri M, Louis VR, Cou-
libaly B, et al. Falciparum malaria in young children of rural Burkina Faso: 
comparison of survey data in 1999 with 2009. Malar J. 2011;10:296.
 62. Ilboudo-Sanogo E, Tiono A, Sagnon N, Cuzin-Ouattara N, Nebie I, 
Sirima SB, et al. Temporal dynamics of malaria transmission in two rural 
areas of Burkina Faso with two ecological differences. J Med Entomol. 
2010;47:618–24.
 63. Geiger C, Agustar HK, Compaore G, Coulibaly B, Sie A, Becher H, et al. 
Declining malaria parasite prevalence and trends of asyymptomatic 
parasitaemia in a seasonal transmission setting in north-western Burkina 
Faso between 2000 and 2009–2012. Malar J. 2013;12:27.
 64. Schrot-Sanyan S, Gaidot-Pagnier S, Abou-Bacar A, Sirima SB, Candolfi 
E. Malaria relevance and diagnosis in febrile Burkina Faso travellers: a 
prospective study. Malar J. 2013;12:270.
 65. Tiono AB, Diarra A, Sanon S, Nebie I, Konate AT, Pagnoni F, et al. Low 
specificity of a malaria rapid diagnostic test during an integrated com-
munity case management trial. Infect Dis Ther. 2013;2:27–36.
 66. Perkins MD, Bell DR. Working without a blidfold: the critical role of diag-
nostics in malaria control. Malar J. 2008;7(Suppl 1):S5.
